Health ❯ Healthcare

Side Effects

Medication Risks Medication Side Effects Gastrointestinal Issues Adverse Reactions Drug Safety Drug Interactions Common Side Effects Drug Reactions Vaccine Reactions Medication Safety

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

Unusually large, sustained reductions reported by Lilly could reshape obesity treatment if regulators approve the drug this year.

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

Moderna’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

UK Flags Safety Profile of GLP-1 Weight-Loss Jabs as One in 10 Report Digestive Side Effects

EMA Backs First Combined COVID-19 and Flu Vaccine for Over-50s in EU

EU Regulators Back First Combined COVID-19 and Flu mRNA Shot for Adults 50 and Over

EMA Backs First Combined COVID–Flu Vaccine for People 50 and Over

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

GLP‑1 Use Under Scrutiny After Study on Tolerability and Delhi OTC Sales

WHO-Backed Reviews Affirm GLP-1 Weight-Loss Gains as Clinicians Flag Safety and Nutrition Gaps

NHS Renews Warnings on PPIs, Sets OTC Pantoprazole Limits

UK Regulator Adds Rare Vision‑Loss Warning to Ozempic, Wegovy and Rybelsus

Honey Energy Supplement Recalled After FDA Finds Undeclared ED Drug

NHS Reminds Sertraline Users to Avoid Grapefruit

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

NHS Guidance on Beclometasone Inhalers Reiterated, Flagging Age Limits and Trace Alcohol in Some Brands

FDA Approves First Oral Weight-Loss GLP-1: Wegovy Pill to Launch in January